Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH-Boc is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand, designed for use in PROTAC (proteolysis-targeting chimera) applications. This compound serves as a crucial building block for synthesizing MI-389, a potent phthalimide-based degrader derived from the multi-targeted receptor tyrosine kinase inhibitor sunitinib. Thalidomide-NH-C6-NH-Boc enables targeted protein degradation, facilitating research into protein regulation and therapeutic discovery in oncology and other fields. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride functions as an E3 ligase ligand-linker conjugate with high affinity for cereblon (CRBN). This compound is pivotal in the development of Proteolysis Targeting Chimeras (PROTACs), offering a strategic approach to induce targeted protein degradation. Its utility extends to research applications in cellular signaling pathways and therapeutic target validation, enabling the exploration of novel treatment modalities in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Piperazine-PEG1-NH2 is an E3 ligase ligand-linker conjugate that leverages the Thalidomide-derived cereblon ligand, facilitating targeted protein degradation through the PROTAC technology framework. This compound is designed for use in research applications aimed at elucidating E3 ligase biology and developing innovative therapeutic strategies. Its unique structure promotes effective interactions with cellular proteins, enhancing the specificity and efficiency of targeted degradation approaches. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from thalidomide with a hexylamine linker. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. It demonstrates significant potential in biochemical research, particularly in drug discovery and development focused on modulating protein levels through E3 ligase recruitment. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG2-C2-NH-Boc is an E3 ligase ligand-linker conjugate that features a thalidomide-based cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound is designed for the synthesis of dBRD9, a selective PROTAC degrader that targets BRD9, facilitating investigations into BAF complex biology. It serves as a valuable tool in research applications focused on targeted protein degradation and the modulation of cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. Its unique structure allows for the recruitment of E3 ligases, making it valuable in studies related to cellular processes and therapeutic development for various diseases. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-PEG2-C2-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in the PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation by promoting interactions with E3 ligases. It is applicable in research focused on cellular protein regulation and therapeutic development in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C3-PEG3-C1-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-based cereblon ligand with a three-unit PEG linker. This compound facilitates targeted protein degradation through PROTAC (Proteolysis Targeting Chimera) technology, enhancing the specificity and efficacy of the therapeutic approach. It is suitable for research applications in the areas of protein modulation and drug discovery. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride is a conjugate that targets E3 ligases, featuring a specific ligand and a flexible linker. This compound exhibits immunomodulatory properties and is utilized in cancer research, aiding investigations into targeted protein degradation and therapeutic strategies. Its unique structure facilitates the study of E3 ligase interactions, making it a valuable tool in oncology and drug development research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Piperazine-PEG2-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a PEG2 linker, facilitating targeted protein degradation through the PROTAC technology. This compound is designed to enhance the specificity and efficacy of protein recruitment to the E3 ligase, making it a valuable tool for investigating the mechanisms of targeted ubiquitination and therapeutic intervention in various diseases. Its applications extend to drug discovery, particularly in the development of innovative treatments for conditions reliant on protein homeostasis. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA is an engineered E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand combined with a three-unit PEG linker suitable for PROTAC technology. This compound facilitates targeted protein degradation through selective E3 ligase recruitment, making it valuable for studies in cellular biology and therapeutic applications. Its unique structure enhances solubility and stability in biological systems, promoting efficient conjugation in research endeavors. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG3-COOH is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand combined with a PEG3 linker. This compound facilitates the targeted ubiquitination of specific proteins through PROTAC technology, promoting their degradation. It serves as a valuable tool for studies involving protein regulation and the development of targeted protein degradation strategies in cellular and molecular biology research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG1-COOH is an E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand, designed for use in PROTAC (Proteolysis Targeting Chimeras) applications. This compound is a versatile click chemistry reagent, possessing an alkyne moiety that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique structure enables targeted protein degradation, making it a valuable tool for research in cellular signaling and therapeutics. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG3-COOH is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand combined with a PEG3 linker, designed for use in PROTAC technology. This compound functions as a click chemistry reagent, possessing an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its applications in targeted protein degradation research make it a valuable tool for exploring protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG3-COOH is an E3 ligase ligand-linker conjugate that combines the thalidomide-derived cereblon ligand with a PEG3 linker. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, enabling targeted protein degradation. Its mechanism allows for selective modulation of protein levels, making it valuable in drug discovery and therapeutic research focused on protein homeostasis and regulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride serves as a synthesized E3 ligase ligand-linker conjugate, featuring a cereblon ligand derived from Thalidomide and a three-unit polyethylene glycol (PEG) linker. This compound is essential for the development of proteolysis-targeting chimeras (PROTACs), enabling targeted degradation of specific proteins in cellular research. Its unique structure facilitates effective interactions with E3 ligases, making it a valuable tool for studying protein regulation and potential therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate, featuring a Thalidomide-based cereblon ligand connected by a PEG3 linker. This compound is designed to facilitate targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology. Its biological activity makes it suitable for applications in protein regulation studies and drug discovery research, particularly in exploring E3 ligase-mediated pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C5-acid is a synthesized E3 ligase ligand-linker conjugate designed to engage cereblon, a key target in the ubiquitin-proteasome system. This compound serves as a crucial component in PROTAC technology, facilitating targeted protein degradation. Its utility in research includes the development of novel therapeutic strategies aimed at modulating protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate designed to target cereblon. This compound utilizes a Thalidomide-based ligand and incorporates a PEG2 linker, facilitating the development of PROTAC (Proteolysis Targeting Chimera) technology. It is primarily used in chemical biology research to modulate protein levels through targeted degradation, making it valuable for investigations in cancer and other diseases where protein regulation is essential. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C8-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from thalidomide, combined with a C8 linker. This compound is designed for use in PROTAC technology, facilitating the targeted degradation of proteins via the ubiquitin-proteasome pathway. Its application in chemical biology includes studies of protein modulation and therapeutic strategies in oncology and other disease models, enabling researchers to explore novel approaches in targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate featuring the Thalidomide-derived cereblon ligand. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enhancing cellular activity against specific protein targets. Its unique structure supports applications in drug development and research focused on modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that integrates the Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker, designed for use in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted degradation of specific proteins via the ubiquitin-proteasome pathway, making it a valuable tool for research in targeted protein modulation. Its application extends to studies in cancer biology and therapeutic development, where selective protein degradation is crucial. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG3-NH-Boc is an E3 Ligase Ligand-Linker Conjugate that targets Cereblon. This compound facilitates the recruitment of the CRBN protein, playing a critical role in the development of targeted protein degradation strategies. The Boc protecting group can be easily removed under acidic conditions, enabling its use in the synthesis of PROTAC molecules. Thalidomide-NH-PEG3-NH-Boc serves as a key intermediate for CRBN-based PROTAC applications in chemical biology research. -
E3 Ligase Ligand-Linker Conjugates Chemical
Thalidomide-4-O-C10-COOH is an E3 ligase ligand-linker conjugate utilized in the synthesis of PROTAC (proteolysis-targeting chimera) compounds. This reagent facilitates targeted protein degradation by promoting the ubiquitination of specific substrates via E3 ligase interaction. It is particularly valuable in drug discovery and development, offering a novel approach for modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound combines the Thalidomide-derived ligand, which targets cereblon, with a PEG4 linker to facilitate the development of bifunctional degraders. Its primary application lies in the degradation of target proteins, enabling novel therapeutic strategies in cancer and other diseases by harnessing the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C6-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand within its structure. This compound serves as a crucial building block in the design and synthesis of PROTACs (proteolysis targeting chimeras). Its unique properties facilitate targeted protein degradation, enabling significant advancements in therapeutic research and drug discovery. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C8-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand paired with a C8 linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimera) applications, facilitating targeted protein degradation through the induction of ubiquitin-proteasome pathway involvement. Its unique structure allows for efficient cellular uptake and modulation of specific protein levels, making it invaluable for research in cellular signaling, disease modeling, and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine hydrochloride is an E3 ligase ligand-linker conjugate, combining a thalidomide derivative that targets cereblon with a PEG4 linker. This compound is designed for use in Proteolysis Targeting Chimera (PROTAC) technology, facilitating the targeted degradation of specific proteins. Its application extends to various studies in cellular signaling and protein homeostasis, making it a valuable reagent for drug discovery and development in the field of targeted therapies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C4-COOH is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from thalidomide with a synthetic linker for targeted protein degradation applications. This compound is designed to facilitate the selective degradation of target proteins through the PROTAC (proteolysis-targeting chimera) mechanism. Its utility spans various biochemical research applications, especially in studies investigating the modulation of intracellular protein levels and the development of therapeutic strategies targeting specific cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, a component of the CRL4 E3 ligase complex. This compound serves as a key element in PROTAC (proteolysis-targeting chimera) technology, facilitating targeted protein degradation. Its biological activity supports research in protein regulation, cellular signaling, and therapeutic strategies for disease intervention. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C6-NHBoc is an E3 ligase ligand-linker conjugate that combines the Thalidomide derivative with a hexyl linker suitable for use in PROTAC technology. This compound functions primarily by targeting cereblon, facilitating the degradation of specific proteins through induced ubiquitination. It is valuable for research applications involving targeted protein degradation and the modulation of signaling pathways associated with various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-Propargyl is an E3 ligase ligand-linker conjugate that features the cereblon ligand derived from Thalidomide, along with a PEG4 linker designed for PROTAC technology. This compound serves as a versatile click chemistry reagent due to its alkyne functionality, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique properties facilitate targeted protein degradation and make it valuable for research applications in drug discovery and protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-NH2 is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through the PROTAC technology, promoting the recruitment of E3 ligases to specific substrates. Its key biological activity makes it a valuable tool for research in cellular regulation, protein homeostasis, and potential therapeutic applications in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-5-PEG3-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation via the PROTAC (proteolysis-targeting chimera) technology, promoting ubiquitination and subsequent proteasomal degradation of specific proteins. Thalidomide-5-PEG3-NH2 is valuable for research applications investigating protein homeostasis and therapeutic strategies in various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG3-NH2 is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol linker. This compound is designed for use in proteolysis-targeting chimera (PROTAC) technology, facilitating the selective degradation of target proteins. By efficiently engaging E3 ligases, Thalidomide-PEG3-NH2 serves as a valuable tool in drug development and biochemical research focused on targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate targeting cereblon, a key component in the ubiquitin-proteasome pathway. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enabling researchers to manipulate cellular protein levels with high specificity. Its unique linker structure enhances the conjugate’s stability and efficacy in various biological applications, making it a valuable tool for studying protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C7-NH2 is an E3 ligase ligand-linker conjugate featuring a thalidomide-derived cereblon ligand and a functionalized linker designed for use in PROTAC technology. This compound exhibits biological activity by recruiting target proteins for ubiquitination and subsequent proteasomal degradation. It is a valuable tool for researchers exploring targeted protein degradation and the modulation of protein levels within cellular systems. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C4-NH2 TFA is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand attached to a linker. This compound serves as a critical component in the development of PROTAC BRD2/BRD4 degrader-1, which effectively degrades the BET proteins BRD4 and BRD2. Its utility in this context highlights its potential in targeted protein degradation research and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C3-NH2 is an E3 ligase ligand-linker conjugate that features a cereblon ligand derived from thalidomide, combined with a linker suitable for PROTAC technology. This compound facilitates targeted protein degradation by promoting the ubiquitination of specific substrates through interactions with the ubiquitin-proteasome system. It is widely utilized in research applications focused on the development and optimization of PROTACs for therapeutic interventions in various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate designed for antibody-drug conjugate (ADC) applications. This compound facilitates the formation of PROTAC iRucaparib-AP6, a highly specific degrader of PARP1, by linking to the target protein via a linker. Its primary mechanism involves enhancing protein degradation pathways, offering significant potential in targeted protein knockdown studies and cancer research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-C8-NH2 hydrochloride functions as an E3 ligase ligand-linker conjugate, incorporating the Thalidomide-derived cereblon ligand along with a suitable linker. This compound is instrumental in the development of proteolysis-targeting chimeras (PROTACs), enabling targeted protein degradation in research applications. Its structural features facilitate selective binding to E3 ligases, making it a valuable tool in drug discovery and cellular function studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG3-NH2 is a synthetic E3 ligase ligand-linker conjugate featuring a thalidomide-derived cereblon ligand. This compound is designed for use in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation through its interaction with E3 ligases. It provides a valuable tool for researchers investigating protein turnover and therapeutic interventions in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-C2-NH2 is an engineered E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand linked to a two-unit PEG moiety. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation by recruiting E3 ligases. It is suitable for investigations into protein homeostasis, signaling pathways, and therapeutic applications in cancer research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG-C2-NH2 is an E3 ligase ligand-linker conjugate designed to target cereblon, a substrate recognition component of the ubiquitin-proteasome system. This compound facilitates protein degradation via PROTAC technology, enabling the selective modulation of protein levels within cells. Its application is particularly relevant in studies of gene regulation and targeted therapy development in various diseases, including cancer. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-4-O-C6-NH2 TFA is a synthetic E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound plays a critical role in the PROTAC dTAG-13, facilitating the selective degradation of FKBP12F36V and BET proteins. Its unique structural features allow for efficient recruitment of E3 ligases, making it a valuable tool in cellular studies of protein regulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amide-C5-NH2 TFA is an E3 ligase ligand-linker conjugate that contains the thalidomide-derived cereblon ligand and a C5 amino linker, facilitating targeted protein degradation via PROTAC technology. This reagent is designed for research applications involving the modulation of protein homeostasis and the therapeutic potential of targeted protein degradation strategies. Its unique structure enables the selective recruitment of E3 ligases, thus enhancing the efficacy of drug discovery and development processes involving the ubiquitin-proteasome system. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-4-O-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate targeting cereblon. This compound incorporates a Thalidomide-based ligand along with a linker designed for use in PROTAC technology, enabling selective protein degradation. Its unique structure allows for the potential modulation of cellular pathways, making it particularly valuable in drug discovery and development research. -
E3 ligase ligand-Linker Conjugate
Thalidomide-NH-PEG4-MS is an E3 ligase ligand-linker conjugate, featuring Thalidomide as a cereblon ligand. It is designed to facilitate targeted protein degradation through the recruitment of E3 ubiquitin ligases. This compound is primarily utilized in the development of PROTACs targeting BCL-XL, enabling effective degradation of specific proteins within cancer research and other cellular studies. -
E3 ligase ligand-linker conjugate
Thalidomide-4-O-C6-NH2 is an engineered E3 ligase ligand-linker conjugate that features a cereblon ligand derived from Thalidomide. This compound serves as a critical component in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation. Its unique structure supports research into molecular modulators and therapeutic interventions in diseases where protein homeostasis is disrupted. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate designed to target the cereblon E3 ligase. This compound utilizes a PEG-based linker, enabling its application in PROTAC (Proteolysis Targeting Chimera) technology for targeted protein degradation. Thalidomide-PEG2-NH2 facilitates the selective modulation of protein levels, providing a valuable tool for research in cellular signaling, cancer biology, and pharmacological studies.
